The dopamine transporter (DAT) inhibitor and nicotinic acetylcholine (nACh) receptor antagonist bupropion is being investigated as a candidate 'agonist' medication for methamphetamine addiction. In addition to its complex pharmacology, bupropion also has two distinct pharmacologically active metabolites. However, the mechanism by which bupropion produces methamphetamine-like 'agonist' effects remains unknown. The aim of the present study was to determine the role of DAT inhibition, nACh receptor antagonism, and the hydroxybupropion metabolites in the methamphetaminelike discriminative stimulus effects of bupropion in rhesus monkeys. In addition, varenicline, a partial agonist at the nACh receptor, and risperidone, a dopamine antagonist, were tested as controls. Monkeys (n = 4) were trained to discriminate 0.18 mg/kg intramuscular methamphetamine from saline in a two-key food-reinforced discrimination procedure. The potency and time course of methamphetamine-like discriminative stimulus effects were determined for all compounds. Bupropion, methylphenidate, and 2S,3S-hydroxybupropion produced full, at least 90%, methamphetamine-like effects. 2R,3R-Hydroxybupropion, mecamylamine, and nicotine also produced full methamphetamine-like effects, but drug potency was more variable between monkeys. Varenicline produced partial methamphetamine-like effects, whereas risperidone did not. Overall, these results suggest DAT inhibition as the major mechanism of the methamphetamine-like 'agonist' effects of bupropion, although nACh receptor antagonism appeared, at least partially, to contribute. Furthermore, the contribution of the 2S,3S-hydroxybupropion metabolite could not be completely ruled out.
Introduction
Methamphetamine addiction remains a worldwide public health problem for which there is no Food and Drug Administration (FDA)-approved pharmacotherapy (Courtney and Ray, 2014) . Furthermore, the 2014 US National Forensic Laboratory Information System midyear report estimates that methamphetamine ranks second only behind cannabis/tetrahydrocannabinol in both the number and the percentage of total drugs submitted for analysis (Drug Enforcement Administration, 2014) . Preclinical drug-discrimination procedures are hypothesized to model and be predictive of the subjective-like drug effects in humans (Schuster and Johanson, 1988; Fischman and Foltin, 1991; Horton et al., 2013) . Furthermore, drug-discrimination procedures have good resolution to examine the pharmacological mechanisms of action of central nervous system-acting compounds and, in particular, abused drugs (Woods et al., 1988; Grant, 1999; Lelas et al., 2000) .
Bupropion is being examined as a candidate 'agonist' pharmacotherapy for methamphetamine addiction (Brensilver et al., 2013) . Consistent with the pharmacological activity of bupropion as a dopamine transporter (DAT), but not norepinephrine transporter (NET) inhibitor (Tidey and Bergman, 1998; Czoty et al., 2004b) , it produces methamphetamine-like discriminative stimulus effects in pigeons (Sasaki et al., 1995) and rats (Munzar and Goldberg, 2000) . Furthermore, bupropion has been shown to antagonize in-vitro methamphetamine-induced dopamine efflux and this effect was hypothesized to be mediated by bupropion inhibiting the DAT and preventing methamphetamine from entering the cell (Simmler et al., 2013) . Moreover, human laboratory studies have suggested that bupropion pretreatment attenuated the subjective and other abuse-related effects of methamphetamine (Rau et al., 2005; Newton et al., 2006) . Overall, this body of literature has been interpreted to suggest that DAT inhibition is a major component of the pharmacological effects of bupropion related to its evaluation as a candidate medication for methamphetamine addiction.
However, the pharmacology of bupropion also includes antagonist activity at nicotinic acetylcholine (nACh) receptors, in addition to DAT and NET inhibition (Fryer and Lukas, 1999; Damaj et al., 2004; Lukas et al., 2010) . These nACh receptor antagonist properties may have implications for bupropion as a pharmacotherapy for methamphetamine addiction. For example, both amphetamine and methamphetamine have been reported to function as nACh receptor agonists (Liu et al., 2003; Garcia-Ratés et al., 2007) or antagonists (Liu et al., 2003) depending on the in-vitro assay. Consistent with these agonist results, nicotine and methamphetamine cross-generalize in drug-discrimination procedures, suggesting a potential shared pharmacological mechanism (Gatch et al., 2008; Bergman, 2010, 2014) . However, whether the nACh receptor antagonist property of bupropion contributes toward its methamphetamine-like effects in vivo has not been systematically explored.
The aim of the present study was to determine the pharmacological mechanism of the methamphetamine-like discriminative stimulus effects of bupropion in rhesus monkeys. To address this aim, we determined the substitution profile of the noncompetitive nACh receptor antagonist mecamylamine and the DAT inhibitor methylphenidate, which does not have in-vitro nACh receptor antagonist properties (Besnard et al., 2012) . In addition, we determined the substitution profile of two pharmacologically active metabolites of bupropion to further clarify the mechanisms of bupropion's methamphetamine-like effects. For example, 2S,3S-hydroxybupropion produces both DAT and NET inhibition and nACh receptor antagonism effects similar to bupropion, whereas 2R,3R-hydroxybupropion primarily functions as an nACh receptor antagonist (Bondarev et al., 2003; Damaj et al., 2004; Lukas et al., 2010) . Finally, the substitution profile of varenicline, an nACh receptor partial agonist, and the dopamine antagonist risperidone were tested as controls. The null hypothesis was that nACh receptor antagonism would not produce methamphetamine-like discriminative stimulus effects. We also hypothesized if either hydroxybupropion metabolite contributed toward the methamphetamine-like discriminative stimulus effects of bupropion, then bupropion might be more potent or may show a longer time course compared with its metabolites.
Methods

Subjects
Four adult male rhesus monkeys (Macaca mulatta) weighing between 6 and 11 kg served as research subjects. Three monkeys (M1510, M1511, M1512) were experimentally naive at the start of methamphetamine-discrimination training and one monkey (M1479) had a previous history of responding under a two-key food-reinforced cocaine versus saline-discrimination procedure. However, this monkey had not been part of cocaine-discrimination studies for 3 months before initiating methamphetaminediscrimination training. Although there are reports of retained drug discriminations following sequential training (McMillan et al., 1996; Li and McMillan, 2003) , the influence of this previous cocaine discrimination should be minimal for the proposed experiments, given the shared pharmacological discriminative stimulus mechanisms between cocaine and methamphetamine or amphetamine (Kamien and Woolverton, 1989; Kleven et al., 1990; Negus et al., 2007) . The monkeys' diet consisted of food biscuits (Lab Diet High Protein Monkey Biscuits; PMI Feeds Inc., St. Louis, Missouri, USA) supplemented with fresh fruit. Water was continuously available in the home chamber. In addition, monkeys could earn 1-g banana-flavored food pellets (5TUR grain-based precision primate tablets; Test Diets, Richmond, Illinois, USA) during the experimental session (described below). A 12 h light-dark cycle was in effect (lights on from 06:00 to 19:00 h), and temperature and humidity levels were controlled and monitored daily. Environmental enrichment consisting of various puzzles and foraging devices in addition to videos or radio was provided during the week at the conclusion of the behavioral sessions. Animal research facilities were licensed by the US Department of Agriculture and accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. The Institutional Animal Care and Use Committee approved both experimental and environmental enrichment protocols.
Methamphetamine-discrimination procedure
Experimental behavioral sessions were conducted in each monkey's home chamber. On the front wall of each chamber was an operant response panel that included three square response keys arranged horizontally; only the left and right keys were used in the present studies. Attached to the back of each panel was a pellet dispenser (ENV-203-1000; Med Associates, St. Albans, Vermont, USA). Equipment operation and data collection were carried out using a Windows-based computer and MED-PC IV Software (Med Associates).
During initial training sessions, 0.1 mg/kg intramuscular (+ )-methamphetamine was administered in a two-key, foodreinforced drug-discrimination procedure. Discrimination training was conducted 5 days per week and consisted of two phases. In phase 1, daily experimental sessions consisted of a single response component. Each component consisted of a 5-min response period, during which the right and left response keys were transilluminated red and green, respectively, and monkeys could earn up to 10 pellets by responding under a fixed-ratio (FR) schedule of food presentation. The FR value was initially set at one and was increased independently on the saline-associated (mean: 25; range: 16-30 training sessions) and methamphetamine-associated (mean: 35; range: 17-53 training sessions) keys to the terminal FR30 schedule of food presentation. Either saline or (0.1 mg/kg methamphetamine) was administered intramuscular ∼ 15 min before the start of the component, and saline-appropriate or methamphetamine-appropriate training sessions were conducted in a double-alternating pattern. Following the administration of saline, only responding on the green key (the saline-appropriate key) produced food, whereas following administration of 0.1 mg/kg methamphetamine, only responding on the red key (the methamphetamine-appropriate key) produced food. Responses on the inappropriate key reset the FR requirement on the appropriate key. Once subjects reached the terminal FR30 schedule for both training conditions, they progressed to phase 2.
In phase 2, daily experimental sessions were composed of two components presented at 3-h intervals, and either saline or 0.1 mg/kg methamphetamine was administered intramuscular ∼ 15 min before the start of each component. Thus, on training days, monkeys would receive a sequence of saline (S) and methamphetamine (M) injections in the order SS, SM, MS, or MM. These training sequences were presented randomly. The goal of this training regimen was to engender daily experience with randomized sequences of salineappropriate and methamphetamine-appropriate response components. The 3-h duration of intercomponent intervals was selected to exceed the time course of discriminative stimulus effects produced by the methamphetamine-training dose in rhesus monkeys and thereby to minimize the effects of methamphetamine administered in earlier trials on performance during later trials on the same day. The criterion for accurate discrimination was at least 85% injection-appropriate responding before delivery of the first reinforcer, at least 90% injection-appropriate responding for the entire component, and response rates at least 0.1 responses/s (sufficient to earn at least one pellet) for all components during 7/8 consecutive sessions. However, none of the monkeys fulfilled the accurate discrimination criterion after 136 training sessions and thus the methamphetamine-training dose was increased to 0.18 mg/kg. All monkeys fulfilled the discrimination criterion within 73 sessions (range: 30-73 sessions) after increasing the methamphetamine dose.
Time-course test sessions were identical to training sessions, except (i) completing the response requirement on either key produced food and (ii) 5-min response components began 10, 30, 56, 100, 180, and 300 min after injection to assess the time course of drug effects. (+ )-Methamphetamine (0.01-0.18mg/kg), ( )-methylphenidate (0.032-0.32 mg/kg), ( )-bupropion (0.32-3.2 mg/kg), 2S,3S-hydroxybupropion (0.32-3.2 mg/kg), 2R,3R-hydroxybupropion (1.0-10.0 mg/kg), ( )-mecamylamine (0.32-1.8 mg/kg), (-)-nicotine (0.1-1.0 mg/kg), varenicline (0.1-1.0 mg/kg), and risperidone (0.01-0.1 mg/kg) were tested up to doses that either produced full substitution for the methamphetamine-training dose or disrupted rates of operant responding in at least two monkeys. Test sessions were separated by at least 3 days and were usually conducted on Tuesdays and Fridays, with training sessions conducted on other weekdays. Test sessions were conducted only if performance during the two preceding training sessions fulfilled the criteria for accurate discrimination described above. All doses from one test drug were determined in one monkey before testing the next drug. Drug doses were counterbalanced between monkeys. Methamphetamine studies were carried out first and methamphetamine doses were determined twice. All other drug test sessions were determined once.
Drugs
(+ )-Methamphetamine HCl, ( )-methylphenidate HCl, and ( )-mecamylamine HCl were provided by the National Institute on Drug Abuse Drug Supply Program (Bethesda, Maryland, USA). Bruce Blough (RTI) synthesized ( )-bupropion HCl, 2S,3S-hydroxybupropion HCl, and 2R,3R-hydroxybupropion HCl using previously described methods (Lukas et al., 2010) . (-)-Nicotine hydrogen bitartrate salt (Sigma Aldrich, St. Louis, Missouri, USA) was dissolved in sterile water and sodium hydroxide was added to the solution to reach a pH of ∼ 5-7. Risperidone (Sigma Aldrich) was dissolved in 2% lactic acid (85% w/w; Sigma Aldrich) and sodium hydroxide was added to reach a pH of ∼ 5-6. All other drugs, including varenicline tartrate (Sigma Aldrich), were dissolved in sterile water. All drug doses are expressed as the salt forms listed above, except for nicotine and risperidone, which were expressed as the base. Nicotine doses were expressed as the free base by multiplying the bitartrate dose by 0.325 (Matta et al., 2007) .
Data analysis
The primary dependent measures were (i) percent methamphetamine-appropriate responding (%MAR) [defined as (number of responses on the methamphetamine-associated key/the total number of responses on both the methamphetamine-associated and saline-associated keys) × 100], and (ii) response rates during each component. These dependent measures were then plotted as a function of time after drug or saline administration. %MAR and response rates were analyzed using a linear mixed-model analysis with drug dose and time as the main fixed effects and subjects as the random effect (JMP Pro 11.1.1; SAS, Cary, North Carolina, USA). A significant drug × time interaction or significant effect of drug dose was followed by the Dunnett's post-hoc test for comparison with vehicle (saline) conditions.
Results
Discriminative stimulus effects of methamphetamine, risperidone, methylphenidate, and bupropion On all training days that preceded test days, monkeys responded almost exclusively on the methamphetamineappropriate key during methamphetamine-training components (mean SEM: 99.9 0.1) and almost exclusively on the saline-appropriate key during saline training components (99.9 0.1). The mean SEM response rates were 1.7 0.3 and 2.0 0.3 responses per second during methamphetamine and saline training components, respectively. Figure 1a shows the potency and time course of saline and methamphetamine to produce MAR. Saline administration produced less than or equal to 10% MAR at all time points and in all test sessions. 0.1 mg/kg methamphetamine produced full substitution, at least 90% MAR, in one monkey and 0.18 mg/kg methamphetamine produced full substitution in all four monkeys. Methamphetamine produced a dose-dependent and time-dependent increase in %MAR (dose: F 3,68.2 = 11.8, P < 0.001; dose × time: F 15,68 = 2.7, P < 0.025). Methamphetamine had no significant effects on rates of operant responding at any time point (Fig. 1d) . In contrast to methamphetamine, 0.1 mg/kg risperidone produced less than 10% MAR (data not shown) and significantly decreased rates of operant responding (risperidone dose: F 2,34 = 4.2, P < 0.025; data not shown).
Figure 1 also shows the potency and time course of methylphenidate (b and e) and bupropion (c and f) to produce methamphetamine-like discriminative stimulus effects. 0.32 mg/kg methylphenidate produced full methamphetamine-like effects and in all three monkeys and these methamphetamine-like effects were significant from 10 to 100 min (dose: F 3,54 = 99.3, P < 0.001; dose × time: F 18,54 = 23.7, P < 0.001). For bupropion, both 1.0 and 3.2 mg/kg produced full substitution in all three monkeys tested. Both bupropion doses produced a dosedependent and time-dependent increase in %MAR, with significant effects up to 56 min (dose: F 3,46 = 18.8, P < 0.001; dose × time: F 15,46 = 3.7, P < 0.001). Figures 1e and f show that neither methylphenidate nor bupropion significantly altered rates of operant responding.
Discriminative stimulus effects of 2S,3S-hydroxybupropion and 2R,3R-hydroxybupropion Figure 2 shows the potency and time course of 2S,3S-hydroxybupropion (a and c) and 2R,3R-hydroxybupropion (b and d) to produce methamphetamine-like discriminative stimulus effects. 1.0 mg/kg 2S,3S-hydroxybupropion produced full substitution in one monkey and 3.2 mg/kg 2S,3S-hydroxybupropion produced full substitution in all three monkeys. 2S,3S-Hydroxybupropion produced a dose-dependent increase in %MAR, with significant effects up to 56 min (dose: F 3,46.8 = 8.5, P < 0.001). For 2R,3R-hydroxybupropion, 3.2 mg/kg produced full substitution in one monkey and 10 mg/kg 2R,3R-hydroxybupropion produced full substitution in all three monkeys, although at different time points and perhaps as a consequence of rate-decreasing effects in two out of three monkeys. Figure 2c shows that 2S,3S-hydroxybupropion did not significantly alter rates of operant responding, whereas Fig. 2d shows that 10 mg/kg represent the group averages for all training sessions preceding test sessions when the saline-associated and methamphetamine-associated keys were correct, respectively. Filled symbols indicate statistical significance compared with saline within a given time point (P < 0.05). Numbers in parentheses indicate the number of subjects contributing to that data point if less than three (methylphenidate or bupropion) or four (methamphetamine) subjects and indicative of a time point where a monkey failed to complete at least one ratio requirement during the response period.
2R,3R-hydroxybupropion significantly (dose: F 3,46 = 3.7, P < 0.02) decreased rates of operant responding compared with saline.
Discriminative stimulus effects of mecamylamine, nicotine, and varenicline Figure 3 shows the potency and time course of ( )-mecamylamine (a and d), (-)-nicotine (b and e), and varenicline to produce methamphetamine-like discriminative-stimulus effects. 1.0 mg/kg mecamylamine produced full substitution in one out of three monkeys and 1.8 mg/kg produced full substitution in two out of three monkeys and partial substitution (73% MAR) in the third monkey. For nicotine, both 0.1 and 0.32 mg/kg produced full substitution for methamphetamine in one out of three monkeys and 1.0 mg/kg nicotine produced full methamphetamine-like discriminative stimulus effects in two out of three monkeys and partial substitution (50% MAR) in the third monkey. In addition, 1.0 mg/kg nicotine produced MAR that was significantly different from saline (dose: F 3,45.6 = 4.3, P < 0.01). In contrast to mecamylamine and nicotine, varenicline failed to produce full substitution at any dose, but 1.0 mg/kg did produce partial substitution in all three monkeys (maximum %MARs of 75, 36, and 37) and this varenicline effect was significantly different from saline (dose: F 3,40.9 = 3.2, P < 0.05). Figure 3d shows lower, but not significant, rates of operant responding after 1.8 mg/kg mecamylamine. Figure 3e shows that 1.0 mg/ kg nicotine significantly decreased rates of operant responding at 10 and 30 min compared with saline (dose: F 3,46 = 12.9, P < 0.001; dose × time: F 15,46 = 3.9, P < 0.001). Figure 3f shows that 1.0 mg/kg varenicline significantly decreased rates of operant responding from 10 to 56 min compared with saline (dose: F 3,46 = 14.5, P < 0.001; dose × time: F 15,46 = 2.2, P < 0.025).
Discussion
The aim of the present study was to determine the pharmacological mechanisms of the methamphetaminelike discriminative stimulus effects of bupropion in rhesus monkeys. There were two main findings. First, drugs Potency and time course of the methamphetamine-like discriminative stimulus effects of (a, c) 2S,3S-hydroxybupropion (0.32-3.2 mg/kg, intramuscular), and (b, d) 2R,3R-hydroxybupropion (1.0-10.0 mg/kg, intramuscular) in rhesus monkeys (n = 3) trained to discriminate methamphetamine (0.18 mg/kg, intramuscular) from saline. Upper vertical axes: percent methamphetamine-appropriate responding. Lower vertical axes: rates of responding in responses per second. Horizontal axes: time in min after injection. Symbols above 'S' and 'M' represent the group averages for all training sessions preceding test sessions when the saline-associated and methamphetamine-associated keys were correct, respectively. Filled symbols indicate statistical significance compared with saline within a given time point (P < 0.05). Numbers in parentheses indicate the number of subjects contributing to that data point if less than three subjects and indicative of a time point where a monkey failed to complete at least one ratio requirement during the response period.
that possessed DAT inhibition produced consistent, dose-dependent and time-dependent methamphetamine-like discriminative stimulus effects. In contrast, compounds that only functioned as nACh receptor antagonists produced less consistent methamphetaminelike discriminative stimulus effects, and at doses that also generally decreased rates of operant responding. Consequently, these results cannot rule out a contributing role of nACh receptor antagonism in the methamphetamine-like discriminative stimulus effects of bupropion. A second main finding was that mecamylamine and nicotine produced qualitatively similar methamphetamine-like discriminative stimulus effects. Although the present results are inconsistent with previous methamphetamine-discrimination results with mecamylamine and nicotine in rats (Gatch et al., 2008; , they are consistent with previous mecamylamine and nicotine results in rhesus monkeys trained to discriminate cocaine (Gould et al., 2011; Banks, 2014) . Overall, these behavioral data suggest potential species differences in the shared pharmacological mechanisms between nACh receptor compounds and monoaminergic compounds that remain to be fully elucidated.
The present study shows that methamphetamine can be used as a discriminative stimulus with training in rhesus monkeys confirms and extends previous results in pigeons (Sasaki et al., 1995) , rodents (French and Witkin, 1993) , squirrel monkeys (Tidey and Bergman, 1998; Desai and Bergman, 2014) , and humans (Sevak et al., 2011) . The time course of the methamphetamine-training dose in the present study is similar to previous time-course results of a slightly larger methamphetamine-training dose in squirrel monkeys (Czoty et al., 2004a) . Furthermore, the present risperidone (negative control) results are consistent with previous human data showing that risperidone does not produce methamphetamine-like subjective effects (Wachtel et al., 2002) . Overall, these results provide an empirical framework for evaluation of the substitution profile of bupropion, its hydroxybupropion metabolites, and the relative contribution of DAT inhibition and 'M' represent the group averages for all training sessions preceding test sessions when the saline-associated and methamphetamine-associated keys were correct, respectively. Filled symbols indicate statistical significance compared with saline within a given time point (P < 0.05). Numbers in parentheses indicate the number of subjects contributing to that data point if less than three subjects and indicative of a time point where a monkey failed to complete at least one ratio requirement during the response period.
Methamphetamine discrimination in rhesus monkeys Banks et al. 201 compared with nACh receptor antagonism toward bupropion's methamphetamine-like effects.
The present study was designed to examine the mechanisms by which bupropion may produce an 'agonist-like' methamphetamine effect. First, bupropion metabolism produces two hydroxybupropion metabolites that have distinct pharmacological activity to inhibit monoamine transporters and/or antagonize nACh receptors (Damaj et al., 2004; Lukas et al., 2010) . If either bupropion metabolite contributed toward the methamphetamine-like stimulus effects of bupropion, then we would predict that the metabolite would also produce methamphetamine-like effects and bupropion would potentially have a longer duration of action compared with the metabolite. Although both bupropion and 2S,3S-hydroxybupropion produced similar time courses of methamphetamine-like effects, suggesting that the contribution of 2S,3S-hydroxybupropion may be minimal, we cannot completely rule out a potential role of 2S,3S-hydroxybupropion as the time to maximum concentration of hydroxybupropion following bupropion administration in nonhuman primates was approximately 30 min (Rytting et al., 2014) . Future pharmacokinetic studies will be required to clarify the role of hydroxybupropion enantiomers in the behavioral effects of bupropion.
A second potential mechanism relates to the complex pharmacological profile of bupropion with affinity to inhibit DAT and NET, and to antagonize nACh receptors (Carroll et al., 2009) . Although DAT inhibition is the presumed primary mechanism of the methamphetamine-like effects of bupropion, the relative contribution of nACh receptor antagonism toward these effects has not been determined. Previous nonhuman primate methamphetamine-discrimination studies have consistently shown that NET inhibitors do not produce full substitution (Czoty et al., 2004b; Tidey and Bergman, 1998) , and as a result of this literature, NET inhibitors were not examined in the present study. The substitution profile of the DAT inhibitors bupropion, 2S,3S-hydroxybupropion, and methylphenidate in the present study extends previous studies with other DAT inhibitors in both rodents and monkeys (Tidey and Bergman, 1998; Czoty et al., 2004a Czoty et al., , 2004b Desai and Bergman, 2014) . The present results also extend these previous results by showing that bupropion and 2S,3S-hydroxybupropion produced full substitution in methamphetamine-trained monkeys. Overall, the present results and the broader scientific literature cited support DAT inhibitors as candidate 'agonist' medications for methamphetamine addiction on the basis of shared discriminative stimulus effects. However, subchronic DAT inhibitor treatments have so far failed to attenuate methamphetamine versus food choice in monkeys (Banks and Blough, 2015; Schwienteck and Banks, 2015) or human laboratory methamphetamine self-administration (Stoops et al., 2015) , and do not produce reliable and robust decreases in methamphetamine use in double blind, placebo-controlled clinical trials (Elkashef et al., 2008; Miles et al., 2013) . Thus, the utility of 'agonist-based' DAT inhibitor medications for methamphetamine addiction remains to be fully elucidated.
Unexpectedly, both mecamylamine and 2R,3R-hydroxybupropion produced full methamphetamine-like discriminative stimulus effects in at least two out of three monkeys. Although there was considerable individual subject variability in the time course of both compounds, most of the variability in %MAR could be accounted for by individual subjects' sensitivity to the rate-decreasing effects produced by mecamylamine and 2R,3R-hydroxybupropion. The substitution profile of mecamylamine in the present study was inconsistent with previous mecamylamine results in methamphetaminetrained rats where mecamylamine produced saline-appropriate responding . Furthermore, the substitution profile of 2R,3R-hydroxybupropion has not been examined in amphetamine-trained or methamphetaminetrained animals, to the best of our knowledge, and this prevents a comparison with the literature. However, the methamphetamine substitution profile of nACh receptor antagonists in the present study is consistent the substitution profile in rhesus monkeys trained to discriminate cocaine (Gould et al., 2011; Banks, 2014) and suggests potential species differences in the pharmacological activity of nicotinic compounds.
Also consistent with the hypothesis of potential species differences in the pharmacological activity of nicotinic compounds, differences were also noted with the present nicotine and varenicline results compared with previous results in rats (Gatch et al., 2008; and squirrel monkeys (Desai and Bergman, 2014) . In general, the substitution profile of nicotine and varenicline for the methamphetamine discriminative stimulus in rhesus monkeys was weaker compared with previous rat and squirrel monkey results. Similar species differences between rats (Desai et al., 2003) and rhesus monkeys (Gould et al., 2011; Mello and Newman, 2011; Banks, 2014) have also been reported for cocaine and nicotinic compounds. Overall, these behavioral results suggest that rhesus monkeys may show decreased expression or function of nicotinic receptors compared with rats, which results in a more variable and weaker substitution profile of nicotinic agonists in monoaminergic discrimination procedures.
